AdJane Unveils Nm-nOMV Mucosal Booster for Respiratory Vaccine Franchises
Image
Delft, Netherlands – September 15, 2026 -- AdJane Biosciences has published a technical white paper detailing a strategy to add a proprietary mucosal-immunity booster to established intramuscular respiratory vaccine franchises, using its clinically validated Nm-nOMV platform derived from Neisseria meningitidis outer membrane vesicles.
The paper, titled 'Boosting mRNA: Mucosal Immunity and a Platform Beyond It,' outlines a heterologous prime-boost regimen: existing intramuscular vaccines would prime systemic immunity, while an intranasal Nm-nOMV dose would generate complementary IgA responses at the respiratory mucosa, the initial entry point for pathogens.